LUPUS NEPHRITIS

This study tests a drug called obinutuzumab in teenagers (12-17) and children (5-11) with active lupus nephritis, a serious kidney complication of lupus. The goal is to see if the drug can help the kidneys recover and reduce disease activity. Participants will receive either the …

This early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (including lupus nephritis) that hasn't improved with standard treatments. The main goals are to check safety, find the best dose, and see early signs of effectiveness. Participants w…

This study tests whether a drug called obinutuzumab, combined with mycophenolate mofetil (MMF), can control lupus-related kidney disease as well as the standard treatment of oral steroids plus MMF, but without the side effects of long-term steroid use. About 196 people with activ…

This study tests a one-time treatment using a patient's own immune cells, modified to target and destroy specific cells causing lupus. It is for adults with severe lupus that has not improved with standard therapies. The goal is to see if this approach can safely control the dise…

This study tests a new treatment called NKX019, which uses specially engineered immune cells (CAR NK cells) to target and calm overactive immune cells that attack the kidneys. It is for people with active lupus nephritis or primary membranous nephropathy who have not responded to…

This early-stage study tests a new cell therapy called FT819 in people with moderate-to-severe autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The goal is to see if it is safe and can reduce disease activity by targeting faulty B-cells. About 244 participan…

This 2-year study looks at how well the drug ianalumab works for adults with lupus nephritis, a kidney disease caused by lupus. Some participants who already responded to treatment will stop the drug to see if they stay well, while others will continue or start open-label ianalum…

This study tests whether adding the experimental drug VIB4920 to standard lupus kidney treatments (mycophenolate mofetil and prednisone) can improve kidney function in people with active lupus nephritis. About 74 adults with lupus and kidney inflammation will receive either VIB49…

This study looks at how well the drug belimumab works in everyday medical practice for adults with active lupus nephritis, a kidney disease caused by lupus. Researchers will follow about 300 people for up to 5 years to see if their kidney function stays stable and if they avoid n…

This study tests a new medicine called ianalumab for people with active lupus nephritis, a kidney problem caused by lupus. About 462 adults will receive either ianalumab or a placebo, added to their usual treatment. The goal is to see if ianalumab can help the kidneys work better…

This study tests a one-time treatment called rapcabtagene autoleucel for people with active lupus or lupus kidney disease that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab, to target and calm the overactive immune syst…

This early-stage study tests a new treatment called CTX112 for people with severe autoimmune diseases like lupus, scleroderma, or myositis that haven't improved with standard therapies. CTX112 uses specially engineered immune cells from a donor to target and attack faulty immune …

This study tests a new treatment combining specially designed immune cells (AD-PluReceptor NK cells) with a drug called tafasitamab and chemotherapy for people with autoimmune disorders like systemic sclerosis, lupus, and lupus nephritis. The goal is to find a safe dose and see i…

This study tests a new treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with kidney inflammation (lupus nephritis). The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells that drive the d…

This study compares two ways of giving the drug mycophenolate mofetil (MMF) to children and teens with lupus nephritis, a kidney disease caused by lupus. One method uses the child's body size to set the dose, while the other adjusts the dose based on drug levels in the blood. The…

This study tests a new treatment called CC-97540 for people with active lupus, including lupus nephritis, who haven't gotten better with standard medicines. The treatment uses specially engineered immune cells (CAR T cells) to target and destroy faulty immune cells causing the di…

This study tests whether combining two drugs, belimumab and voclosporin, along with standard therapy, can help more people with lupus kidney disease achieve complete kidney remission. The trial involves 30 adults with active lupus nephritis. The goal is to improve kidney function…

This study tests a new treatment called obe-cel for people with severe lupus that affects the kidneys and hasn't improved with standard therapies. Obe-cel is designed to destroy harmful immune cells that drive the disease. The trial will enroll 35 people aged 12 to 65 and check i…

This study tests an experimental drug called iptacopan added to usual treatment for people with active lupus nephritis, a serious kidney complication of lupus. The goal is to see if it helps more patients achieve complete kidney recovery within 24 weeks. About 240 adults with con…

This study is testing a new oral medication called IPG11406 for people with lupus nephritis, a kidney complication of lupus. The main goal is to check if the drug is safe and tolerable, and to see early signs it might help reduce kidney damage. About 36 adults aged 18 to 70 with …

This study looks at whether doing a repeat kidney biopsy one year after starting treatment for lupus nephritis helps doctors make better treatment decisions. About 206 people with a first episode of lupus nephritis will be randomly assigned to either get the repeat biopsy or not.…

This study watches 400 people with lupus nephritis who are starting LUPKYNIS to see how safe the drug is in real life and how well it works. Researchers will collect information on side effects and other safety events. The goal is to learn more about the drug's effects outside of…

This study is building a large database and sample bank from 3500 people with lupus. Researchers will use this information to better understand the disease and find new ways to treat it. Participants provide medical data and biospecimens over time.